Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines Publisher Pubmed



Hajighasemlou S1, 2 ; Alebouyeh M1 ; Rastegar H1 ; Manzari MT1 ; Mirmoghtadaei M3 ; Moayedi B4 ; Ahmadzadeh M5 ; Parvizpour F2 ; Johari B6 ; Naeini MM7 ; Farajollahi MM7, 8, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Iran Food and Drug Administration, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Tehran University of Medical Sciences, International Campus (TUMS-IC), Tehran, Iran
  4. 4. Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Biotechnology, Pasteur Institute of Iran, Tehran, Iran
  7. 7. Cellular and Molecular Research Centre, Iran University of Medical Sciences, Tehran, Iran
  8. 8. Alborz Food and Drug Laboratory, Fardis, Alborz, Iran
  9. 9. Department of Medical Biotechnology, Iran University of Medical Sciences, Tehran, Iran

Source: Asian Pacific Journal of Cancer Prevention Published:2015


Abstract

Background: Worldwide, breast cancer is the most common cancer diagnosed among women and a leading cause of cancer deaths. The age of onset in Iran has become reduced by a decade for unknown reasons. Herceptin, a humanized monoclonal antibody, is a target therapy for breast cancer cells with over expression of HER2-neu receptors, but it is an expensive drug with only 20% beneficial rate of survival. This study introduces a novel approach to enhance the efficacy of this drug through immunoconjugation of the antibody to botulinum toxin. Decreasing the cost and adverse effects of the antibody were secondary goals of this study. Materials and Methods: Botulinum toxin was conjugated with Herceptin using heterobifunctional cross linkers, succinimidyl acetylthiopropionate (SATP) and sulfo-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) according to the supplier's guidelines and tested on two breast cancer cell lines: SK-BR-3 and BT-474. Toxin and Herceptin were also used separately as controls. The cytotoxicity assay was also performed using the new bioconjugate on cultured cells with Alamar blue and a fluorescence plate reader. Results: Herceptin-Toxin bioconjugation significantly improved Herceptin efficacy on both breast cancer cell lines when compared to the control group. Conclusions: Toxin-Herceptin bioconjugation can be a potential candidate with increased efficiency for treating breast cancer patients with over expression of the HER2 receptor.
Other Related Docs
9. Production and Characterization of New Anti-Her2 Monoclonal Antibodies, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2015)